T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.44 SGD -2.22%
Market Cap: 584.2m SGD
Have any thoughts about
Talkmed Group Ltd?
Write Note

Intrinsic Value

The intrinsic value of one 5G3 stock under the Base Case scenario is 0.31 SGD. Compared to the current market price of 0.44 SGD, Talkmed Group Ltd is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

5G3 Intrinsic Value
0.31 SGD
Overvaluation 30%
Intrinsic Value
Price
T
Worst Case
Base Case
Best Case

Valuation Backtest
Talkmed Group Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for 5G3 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about 5G3?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Talkmed Group Ltd

Provide an overview of the primary business activities
of Talkmed Group Ltd.

What unique competitive advantages
does Talkmed Group Ltd hold over its rivals?

What risks and challenges
does Talkmed Group Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Talkmed Group Ltd.

Provide P/S
for Talkmed Group Ltd.

Provide P/E
for Talkmed Group Ltd.

Provide P/OCF
for Talkmed Group Ltd.

Provide P/FCFE
for Talkmed Group Ltd.

Provide P/B
for Talkmed Group Ltd.

Provide EV/S
for Talkmed Group Ltd.

Provide EV/GP
for Talkmed Group Ltd.

Provide EV/EBITDA
for Talkmed Group Ltd.

Provide EV/EBIT
for Talkmed Group Ltd.

Provide EV/OCF
for Talkmed Group Ltd.

Provide EV/FCFF
for Talkmed Group Ltd.

Provide EV/IC
for Talkmed Group Ltd.

Show me price targets
for Talkmed Group Ltd made by professional analysts.

What are the Revenue projections
for Talkmed Group Ltd?

How accurate were the past Revenue estimates
for Talkmed Group Ltd?

What are the Net Income projections
for Talkmed Group Ltd?

How accurate were the past Net Income estimates
for Talkmed Group Ltd?

What are the EPS projections
for Talkmed Group Ltd?

How accurate were the past EPS estimates
for Talkmed Group Ltd?

What are the EBIT projections
for Talkmed Group Ltd?

How accurate were the past EBIT estimates
for Talkmed Group Ltd?

Compare the revenue forecasts
for Talkmed Group Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Talkmed Group Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Talkmed Group Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Talkmed Group Ltd compared to its peers.

Compare the P/E ratios
of Talkmed Group Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Talkmed Group Ltd with its peers.

Analyze the financial leverage
of Talkmed Group Ltd compared to its main competitors.

Show all profitability ratios
for Talkmed Group Ltd.

Provide ROE
for Talkmed Group Ltd.

Provide ROA
for Talkmed Group Ltd.

Provide ROIC
for Talkmed Group Ltd.

Provide ROCE
for Talkmed Group Ltd.

Provide Gross Margin
for Talkmed Group Ltd.

Provide Operating Margin
for Talkmed Group Ltd.

Provide Net Margin
for Talkmed Group Ltd.

Provide FCF Margin
for Talkmed Group Ltd.

Show all solvency ratios
for Talkmed Group Ltd.

Provide D/E Ratio
for Talkmed Group Ltd.

Provide D/A Ratio
for Talkmed Group Ltd.

Provide Interest Coverage Ratio
for Talkmed Group Ltd.

Provide Altman Z-Score Ratio
for Talkmed Group Ltd.

Provide Quick Ratio
for Talkmed Group Ltd.

Provide Current Ratio
for Talkmed Group Ltd.

Provide Cash Ratio
for Talkmed Group Ltd.

What is the historical Revenue growth
over the last 5 years for Talkmed Group Ltd?

What is the historical Net Income growth
over the last 5 years for Talkmed Group Ltd?

What is the current Free Cash Flow
of Talkmed Group Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Talkmed Group Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Talkmed Group Ltd

Current Assets 92.7m
Cash & Short-Term Investments 85.7m
Receivables 5.5m
Other Current Assets 1.5m
Non-Current Assets 11.2m
Long-Term Investments 2.3m
PP&E 8.7m
Other Non-Current Assets 198k
Current Liabilities 24m
Accounts Payable 4.4m
Other Current Liabilities 19.6m
Non-Current Liabilities -3.1m
Long-Term Debt 4.1m
Other Non-Current Liabilities -7.2m
Efficiency

Earnings Waterfall
Talkmed Group Ltd

Revenue
79.1m SGD
Operating Expenses
-46.3m SGD
Operating Income
32.8m SGD
Other Expenses
-5.1m SGD
Net Income
27.7m SGD

Free Cash Flow Analysis
Talkmed Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

5G3 Profitability Score
Profitability Due Diligence

Talkmed Group Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Exceptional 3-Year Average ROE
Positive Operating Income
78/100
Profitability
Score

Talkmed Group Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.

5G3 Solvency Score
Solvency Due Diligence

Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Long-Term Solvency
Negative Net Debt
99/100
Solvency
Score

Talkmed Group Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

5G3 Price Targets Summary
Talkmed Group Ltd

There are no price targets for 5G3.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for 5G3?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 5G3 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Talkmed Group Ltd

Country

Singapore

Industry

Health Care

Market Cap

597m SGD

Dividend Yield

6.14%

Description

TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).

Contact

101 Thomson Road, #09-02 United Square
+6562586918
www.talkmed.com.sg

IPO

2014-01-30

Employees

-

Officers

CEO & Executive Director
Dr. Peng Tiam Ang
Group CFO & Joint Company Secretary
Mr. Boon Yong Lee
Chief Operating Officer
Dr. Kei Siong Khoo
Joint Company Secretary
Ms. Jacqueline Anne Low

See Also

Discover More
What is the Intrinsic Value of one 5G3 stock?

The intrinsic value of one 5G3 stock under the Base Case scenario is 0.31 SGD.

Is 5G3 stock undervalued or overvalued?

Compared to the current market price of 0.44 SGD, Talkmed Group Ltd is Overvalued by 30%.

Back to Top